PROJECT SUMMARY BIOINFORMATICS AND DATA INTEGRATION CORE (BDIC) Systematic analysis of the translational relevance of marmoset models of Alzheimer’s disease will require a centralized data management and analysis team that interacts with all Projects and Cores. To this end, the Bioinformatics and Data Integration Core (BDIC) will: generate multi-omics data to characterize marmoset genomes, proteomes, and transcriptomes; provide data processing and storage for sequencing, genomics, and similar molecular data; import and curate data and results from relevant human genetic and genomic studies; create the processes and tools to systematically align human and marmoset data for multi-scale cross-species analyses; and create and populate a data-sharing platform for broad and open access of all data and protocols. This core will address this goal through the following aims: (1) generate, process, and manage genome-scale molecular data from aging outbred and mutant marmoset populations; (2) develop and apply statistical methods for rigorous marmoset and cross-species data analysis based on matched multi-omic measures; and (3) broadly disseminate data and protocols through open science platforms to ensure reliable replication of studies and reuse of all marmoset data. The BDIC will build upon existing resources such as the AD Knowledge Portal, the Agora platform, Alz-PED, and the workflows from existing NIA-funded consortia, including AMP-AD, TREAT-AD, MODEL-AD, MOVE-AD, and Resilience-AD. We will add the outcomes of this marmoset-centered project to this foundation to optimize translational relevance and responsible data reuse. In achieving these goals, the BDIC will manage data and facilitate its integrated analysis in multiple contexts across multiple project components. Internal and external researchers will be positioned to efficiently and reliably assess the disease relevance of marmoset models and associated phenotypes. Finally, the broader research community will be empowered to use the marmoset as a model to understand and guide their research into therapeutics for Alzheimer’s disease.